The FDA told Whoop, Inc. directly that their flagship blood pressure feature could cause users to suffer stroke, heart attack, heart failure, kidney failure, cognitive decline, and premature death — and Whoop sold the product anyway, to hundreds of thousands of people, at a premium price, without ever telling a single customer the truth.
How Whoop, Inc. Illegally Monetized Medical Misinformation
Whoop Membership Tiers: What You Pay vs. What You Get
Whoop, Inc. built a pricing ladder with a single purpose: convince health-conscious consumers to pay more money for a device that claimed to do something it had no legal right to do. The top tier, the Whoop Life membership at $359 per year (about the same as filling a car’s gas tank twelve times), cost $210 more per year than the base Whoop One membership (the difference between a week of groceries for a family of four and then some) specifically because it promised “medical-grade” blood pressure readings. The whole pyramid rested on that promise. The FDA confirmed it was a lie.
The Architecture of the Con
They Designed a Premium Tier Around a Feature They Never Cleared
Whoop structured its entire product line to funnel consumers toward the highest-cost tier. The Whoop One, at $150 per year (about the cost of a Netflix subscription for a year plus a couple of months), was for “fitness performance.” The Whoop Peak, at $239 per year, was for “longevity and health management.” But the Whoop Life, at $359 per year, was the one that promised “advanced health and heart monitoring” through its flagship Blood Pressure Insights feature. The distinction was deliberate, calculated, and, according to federal regulators, fraudulent.
The Blood Pressure Insights (BPI) feature promised users they could “get systolic and diastolic ranges” from their wrist every single morning. The device delivered those readings on a color-coded gauge: green for normal, yellow for caution, orange for concern. That design is not a wellness tool. It is a diagnostic interface. The FDA reviewed it and said so in writing.
Whoop crowned the device the “most powerful WHOOP ever, delivering medical-grade health and performance insights” and explicitly called itself “the only wearable offering daily blood pressure insights in a seamless wrist-based format.” Every word of that marketing was designed to justify the price premium. None of it was cleared by the agency that exists to make sure medical technology actually works.
— Class Action Complaint, Rowe v. Whoop, Inc., November 18, 2025
They Put “Medical-Grade” Right On The Box
The packaging for the Whoop MG Device called it a “Heart Screener” on the front. The back of the box went further: “Medical-grade Heart Screener with ECG for AFib detection and heart health insights.” This was not fine print. This was the headline promise printed on the physical product sold at retail stores including Best Buy. Plaintiff Wendell Rowe read those words in an Alameda County Best Buy, believed them, and paid accordingly.
Whoop also published a marketing article on May 8, 2025, calling BPI a “groundbreaking feature” offering “patent-pending technology” delivering “daily systolic and diastolic blood pressure estimations.” The article included a section specifically explaining how blood pressure connects to sleep, stress, and overall wellness — framing designed to make the reader feel the data was essential, actionable, and medically meaningful. It was uncleared, unauthorized, and illegal under California’s Sherman Law.
The Non-Financial Ledger
What Was Really Stolen From Every Person Who Bought This Device
When you buy a device that tells you your blood pressure is fine, you make decisions. You skip the cardiologist appointment because the little green gauge on your wrist says you are okay. You dismiss the headache. You chalk up the fatigue to a bad night’s sleep. You trust the science-y looking number on your phone screen because a Boston tech company told you — in writing, on the packaging, on the website, in a whole dedicated marketing article — that it was “medical-grade.” That trust is not naive. It is the reasonable response to a product that spent real money advertising itself as medically legitimate.
Hypertension is called the “silent killer” because it presents without symptoms. You do not feel high blood pressure. You feel fine right up until you do not. That is exactly why ambulatory blood pressure monitoring has been worked into American Heart Association guidelines — because catching elevated numbers between doctor visits can prevent strokes and heart attacks. Whoop exploited that medical reality. The company understood that consumers were turning to wearables precisely because they wanted to catch something their bodies were not telling them. Whoop sold them a device that provided false reassurance instead of real data, undetectable to the user, indistinguishable from legitimate monitoring.
The FDA’s letter describes the specific chain of medical harm with clinical precision: a person with hypertension whose Whoop device reads falsely low sees a green gauge and relaxes. Then at the doctor’s office, when the real reading comes back elevated, it gets written off as “white coat hypertension” — the common phenomenon of anxiety pushing numbers up in a clinical setting. The falsely normal home readings provide the “proof” that the doctor’s numbers are the anomaly. Treatment gets delayed. The condition progresses. The FDA names the endpoints: stroke, heart attack, heart failure, kidney failure, cognitive decline, premature death. These are the people Whoop’s marketing reached. These are the conditions Whoop’s uncleared device was playing with.
Beyond the physical risk, there is the specific indignity of being targeted because you care about your health. The Whoop Life customer is not someone who stumbled onto a cheap gadget. This is a person who researched membership tiers, compared features, read marketing copy, and made a deliberate, considered investment in their own wellness. The complaint describes plaintiff Wendell Rowe doing exactly this: reviewing the website, comparing the One, Peak, and Life tiers, reading the packaging at the store, making a reasoned decision. Whoop designed its funnel to reach precisely that type of careful, health-motivated consumer. It sold them false safety at a premium. The betrayal is not incidental. The betrayal was the product.
Legal Receipts
Every Word They Tried to Hide, Sourced and On Record
“Providing blood pressure estimation is not a low-risk function. High blood pressure is the most prevalent modifiable risk factor for cardiovascular disease in this country. Although traditionally blood pressure has been checked in a healthcare setting, ambulatory blood pressure checks are now in the American Heart Association (AHA) guidelines, and individuals are encouraged to check their own blood pressure at home.” — FDA Warning Letter to Whoop, Inc., July 14, 2025
“An erroneously low or high blood pressure reading can have significant consequences for the user. For example, if an individual with hypertension used a device that resulted in falsely low blood pressure measurements, those results could lead to inappropriate reassurance that they have a normal blood pressure. This could be compounded by elevated blood pressure measurements at their doctor’s office which may be misinterpreted as white coat hypertension.” — FDA Warning Letter to Whoop, Inc., July 14, 2025
“This can result in a delay or even a lack of treatment, which can result in serious impacts to that patient’s cardiovascular health and end organ damage. These include stroke, heart attack, heart failure, kidney failure, cognitive decline, and premature death.” — FDA Warning Letter to Whoop, Inc., July 14, 2025
“Even accounting for BPI’s disclaimers, they do not change this conclusion, because they are insufficient to outweigh the fact that the product is, by design, intended to provide a blood pressure estimation that is inherently associated with the diagnosis of a disease or condition. The inefficacy of such disclaimers is demonstrated by evidence of individuals using BPI to monitor their hypertension.” — FDA Warning Letter to Whoop, Inc., July 14, 2025 (quoted in Class Action Complaint)
“Inaccurate or imprecise measurements are especially concerning for a disease like hypertension because it often presents without physical symptoms.” — FDA Warning Letter to Whoop, Inc., July 14, 2025
“Some believe that once you define a feature as ‘for wellness,’ it automatically becomes non-medical, no matter what it measures. But as a medical doctor, I can say that some features carry diagnostic weight no matter how gently you present them. Blood pressure is one of those.” — Yusuf Cem Kaplan, MD, former medical advisor at Flo Health, LinkedIn post (cited in Complaint)
“Defendant had an improper motive — to derive financial gain at the expense of accuracy or truthfulness — in its practices related to the labeling and advertising of the Products.” — Class Action Complaint, Rowe v. Whoop, Inc., November 18, 2025
Societal Impact Mapping
Public Health: A Device Built to Manufacture False Reassurance
Hypertension kills. According to the source material and the expert cited within it, high blood pressure is the number one modifiable risk factor for cardiovascular disease in the United States. The American Heart Association has specifically updated its guidelines to encourage home blood pressure monitoring because catching elevated readings between doctor visits can prevent serious cardiac events. Whoop stepped directly into that clinical gap — the space between scheduled appointments where early detection happens — and filled it with uncertified, uncleared data dressed up as medical insight.
The FDA did not speculate about harm. It described the exact clinical pathway: a Whoop user with undiagnosed or under-treated hypertension sees falsely normal readings from their wristband every morning. At their next doctor’s visit, when the real number is elevated, both the patient and potentially the physician now have “evidence” suggesting it is anxiety-driven white coat hypertension, rather than a genuine chronic condition requiring treatment. The false data from the wrist device does not just fail to help. It actively introduces noise into the diagnostic process. It corrupts the conversation between patient and doctor.
The FDA further noted something that should make every Whoop Life customer feel sick: there was already real-world evidence of people using the BPI feature to monitor existing hypertension diagnoses. These are not hypothetical future harms. People with known high blood pressure were actively relying on an uncleared wristband device to track a serious medical condition. The FDA used this as direct proof that no amount of fine-print disclaimers could neutralize the medical intent of the product. Whoop built a device people used as a substitute for proper monitoring. It sold them that device without authorization. That is the public health ledger.
Economic Inequality: The Premium Trap for People Who Can Least Afford Medical Errors
The people most motivated to monitor their own blood pressure at home are often the people with the least consistent access to healthcare. Routine doctor visits, specialist appointments, and ambulatory blood pressure monitoring through clinical channels carry real costs — in time, in copays, in transportation, in lost wages from taking time off work. Wearable health tech markets itself explicitly to this gap: “monitor your health from your wrist, no appointment needed.” Whoop’s $359 per year Life membership (about the same as one emergency room copay, or four months of minimum wage work for several hours) was positioned as a solution to exactly that access problem.
But the premium price layer adds a second injury. The class action complaint establishes that no reasonable consumer would pay $359 per year for Whoop Life without the BPI feature. The $210 annual premium over the base tier (the equivalent of a month of prescription medications for someone on a fixed income) was the price of the medical-grade promise. People who stretched their budgets to pay for what they believed was legitimate health monitoring got neither medical accuracy nor their money back. They paid extra for a product the law says could not be legally sold.
The complaint also notes an injury to competition itself: Whoop’s fraudulent claims prevented consumers from making informed comparisons with competing products that played by the rules. Legitimate medical device makers spend years and millions of dollars going through the FDA clearance process. Whoop bypassed that process entirely, captured premium market share on the strength of false claims, and undercut every competitor who did the work honestly. The economic distortion runs from individual wallets all the way to the structure of the medical device market.
The “Cost of a Life” Metric
Annual Whoop Life price (similar to filling a gas tank 12 times)
Minimum aggregate class damages threshold — enough to fund a small community health clinic for several years
Estimated California class members described as “hundreds of thousands” in the complaint
Premium Extraction Per User: Whoop Life vs. Lower Tiers
What Now?
Who Is Responsible and Where to Put Pressure
The class action complaint names Whoop, Inc. as the sole defendant. The company operates out of its headquarters at One Kenmore Square, Suite 601, Boston, Massachusetts 02215. The decisions to market, label, and sell the Whoop Life Membership with unauthorized blood pressure claims were made at that address. The following corporate roles at Whoop, Inc. bear direct responsibility for the marketing, advertising, labeling, and corporate operations described in the complaint:
I have another article on a different WHOOP corporate misconduct here that you can read
Explore by category
Product Safety Violations
When companies sell dangerous goods, consumers pay the price.
View Cases →Financial Fraud & Corruption
Lies, scams, and executive impunity that distort markets.
View Cases →Related posts:
